Factors associated with complicated buprenorphine inductions

March 2, 2016

Abstract: Despite data supporting its efficacy, barriers to implementation of buprenorphine for office-based treatment are present. Complications can occur during buprenorphine inductions, yet few published studies have examined this phase of treatment. To examine factors associated with complications during buprenorphine induction, we conducted a retrospective chart review of the first 107 patients receiving buprenorphine treatment […]

Read the full article →

Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers

March 2, 2016

Conclusions  These results suggest that buprenorphine and buprenorphine/naloxone have similar abuse potential in non-dependent opioid abusers, and that the addition of naloxone at these doses and in this dose ratio confers no evident advantage for decreasing the abuse potential of intramuscular or sublingual buprenorphine in this population. Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-010-1898-4Authors Angela N. […]

Read the full article →

Cost-effectiveness of extended buprenorphine–naloxone treatment for opioid-dependent youth: data from a randomized trial

March 2, 2016

Conclusions Extended BUP treatment relative to brief detoxification is cost effective in the US health-care system for the outpatient treatment of opioid-dependent youth. (Source: Addiction)

Read the full article →

SUBOXONE (Buprenorphine Hydrochloride And Naloxone Hydrochloride) Tablet [Physicians Total Care, Inc.]

March 2, 2016

Updated Date: Jul 29, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Read the full article →

Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects

March 2, 2016

Abstract: Previous reports have demonstrated greater antinociception following administration of a buprenorphine/naloxone combination compared to buprenorphine alone among healthy volunteers. The aim of the current investigation was to determine whether buprenorphine antinociception could be enhanced with the addition of ultra-low dose naltrexone, using a range of dose ratios. A repeated-measures, double-blind, cross-over trial was undertaken […]

Read the full article →

Drug Treatment as HIV Prevention: Expanding Treatment Options

March 2, 2016

Abstract  Research conducted during the first 20 years of the AIDS epidemic provided a solid foundation of data supporting methadone treatment as HIV prevention. Drug users in methadone treatment were consistently found to reduce the frequency of drug use, risk behaviors, and infections. These data have been consistent over time and across cultural settings and have been […]

Read the full article →

Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia

March 2, 2016

Conclusions: In Malaysia, BUP and BNX IDU occur among heroin IDUs. The introduction of BNX and withdrawal of BUP may have helped to reduce, but did not eliminate the problems with diversion and abuse. (Source: Drug and Alcohol Dependence) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas […]

Read the full article →

Reckitt Benckiser Pharmaceuticals Inc. Receives FDA Approval for Suboxone (buprenorphine and naloxone) Sublingual Film C-III

March 2, 2016

Richmond, VA (31st August 2010) – Reckitt Benckiser Pharmaceuticals Inc. today announces that it has received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) to manufacture and market Suboxone… (Source: Drugs.com – New Drug Approvals)

Read the full article →

MonoSol Rx Announces Reckitt Benckiser FDA Approval Of Suboxone® Sublingual Film For Treatment Of Opioid Dependence

March 2, 2016

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in film pharmaceutical products, today announced that its partner, Reckitt Benckiser Pharmaceuticals Inc., a wholly-owned subsidiary of Reckitt Benckiser Group plc (LSE: RB), has received approval from the U.S. Food and Drug Administration (FDA) to market Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual […]

Read the full article →

Opioid Dependence Drug Gets Okay for New Delivery Mode

March 2, 2016

WASHINGTON (MedPage Today) — The FDA has approved a new sublingual film formulation of the opioid dependence treatment combination buprenorphrine/naloxone (Suboxone). (Source: MedPage Today Public Health)

Read the full article →

← Previous Entries

Next Entries →